In gastric and other digestive tract cancers, CTRP6 may promote tumor progression by activating the MAPK/ERK1/2 pathway, enhancing inflammatory cytokine production such as IL-1β, IL-6, and TNF-α [21]. Here, C1QTNF6 is linked to neoplasm.